This is a multicenter, randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of AVTX-801 in subjects with SLC35A2-CDG

开始日期2025-06-01

申办/合作机构

Icahn School of Medicine at Mount Sinai

[+3]

NCT05402332

/ Not yet recruiting临床2期IIT

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-Controlled, Crossover, Trial Assessing the Efficacy, Safety, and Tolerability of AVTX-801 in Subjects With Phosphoglucomutase 1 Deficiency Related Congenital Disorders of Glycosylation (PGM1-CDG)

This is a clinical trial to evaluate the efficacy of AVTX-801 (D-galactose) on the clinical manifestations of PGM1-CDG in participants currently taking D-galactose.

开始日期2025-03-01

申办/合作机构

Icahn School of Medicine at Mount Sinai

[+1]

NCT05986500

/ RecruitingN/AIIT

The GALAXY-1 Project: Galactose - the Ideal Carbohydrate Supplement for Exercise

"The understanding of the two sugars, glucose and fructose, has been thoroughly investigated regarding their impact on human metabolism during exercise. The consumption of the sugar galactose is an intriguing alternative and can be beneficial, especially for individuals with type 1 Diabetes, as it reduces the need for insulin to maintain normal blood sugar levels. Additionally, galactose oxidation rates during exercise are only 50-60% compared to glucose, primarily due to liver storage and/or the requirement for conversion to glucose in the liver before oxidation. This delay in metabolism can prevent hyperglycemia before exercise and provide extended protection against episodes of hypoglycemia during and after exercise through a moderate and prolonged glycemic response.
The purpose of this experiment is to investigate whether galactose is taken up by skeletal muscles and the heart in response to exercise or hyperinsulinemia. Using non-invasive 18F-FDGal PET, the investigators will examine this in a randomized controlled study design. The results could contribute to updating dietary recommendations, particularly for individuals with type 1 diabetes who struggle to maintain normal blood sugar levels during and after exercise."

开始日期2024-02-12

申办/合作机构

University of Aarhus

100 项与 D-Galactose 相关的临床结果

登录后查看更多信息

100 项与 D-Galactose 相关的转化医学

登录后查看更多信息

100 项与 D-Galactose 相关的专利（医药）

登录后查看更多信息

59,766

项与 D-Galactose 相关的文献（医药）

2025-07-01·SEPARATION AND PURIFICATION TECHNOLOGY

Pilot scale hydrodynamic cavitation and hot-water extraction of Norway spruce bark yield antimicrobial and polyphenol-rich fractions

作者: Liimatainen, Jaana ; Kilpelainen, Petri ; Tienaho, Jenni ; Meneguzzo, Francesco ; Jyske, Tuula ; Kaipanen, Kalle ; Rudolfsson, Magnus ; Tagliavento, Luca ; Myllymaki, Laura ; Marjomaki, Varpu ; Karonen, Maarit ; Ruuttunen, Kyosti ; Hagerman, Ann E.

Norway spruce (Picea abies [L.] Karst) tree bark contains high concentrations of polyphenolic compounds with antibacterial, antioxidant, and antiviral properties.While laboratory-scale extraction studies are relatively abundant, the behavior of biomass properties and compound profiles during upscaled processing have remained underexplored.This study addresses the gap by assessing the industrial feasibility of using an industrial-scale assortment of bark biomass obtained directly from a sawmill.It compares two green pilot-scale extraction methods using only water as the solvent: hydrodynamic cavitation and hot-water extractionThe resulting lyophilized and spray-dried extracts were analyzed for their antibacterial, antiviral, and antioxidant activities, as well as their chem. composition, including carbohydrate, stilbene, tannin, and terpene contents.To further evaluate the industrial potential, a tech. feasibility anal. was conducted, highlighting material and energy balances for both extraction processes and identifying areas for improvement.The findings indicate that both extraction methods effectively yielded polyphenol-rich extracts with desirable bioactivities.Notably, hot-water extracts, with slightly higher condensed tannin and stilbene content, exhibited higher antioxidant activity and greater efficacy against enterovirus (coxsackievirus A9), while hydrodynamic cavitation products showed higher activity against gram-pos. and gram-neg. bacteria.Lyophilization resulted in slightly lower chain-length, but higher concentrations of tannins and stilbenes compared to spray-drying.Overall, this study demonstrates that upscaled processing of spruce bark can effectively and sustainably produce com. viable extraction products.

2025-06-01·SEPARATION AND PURIFICATION TECHNOLOGY

New family of type V natural hydrophobic deep eutectic solvents based on thymol-acetamide/acetanilide: Characteristics, intermolecular interactions and applications in liquid–liquid extraction

作者: Sadeghi, Rahmat ; Ebrahimi, Nosaibah ; Rafati, Solmaz

To develop type V hydrophobic thymol-based Deep Eutectic Solvents (DESs) with low viscosity for liquid-liquid extraction, this work briefly reviews the thymol-based DESs reported in the literature, along with their various applications, and investigates the potential for DES formation between thymol and new materials.For this purpose, 39 combinations of thymol with different amino acids (5), acids (10), carbohydrates (13), amides (2), alkylammonium halides (4), and other compounds (5) were screened, resulting in the preparation of two new thymol-acetamide and thymol-acetanilide-based DESs.To identify the optimal molar ratios for DES formation, various combinations of thymol with acetamide and acetanilide were prepared, and their abilities to form stable liquids at room temperature, along with their thermal properties, were evaluated.Based on the solid-liquid equilibrium (SLE) phase diagrams, it was found that stable liquids at ambient temperature were formed within the composition ranges of x_ACM = 0.29-0.40 (2.5:1-1.5:1) for THY:ACM and x_ACN = 0.29-0.33 (2.5:1 - 2:1) for THY:ACN.The mixtures with a molar ratio 2:1 were selected for further study, and their intermol. interactions, characteristics, and applications in dye extraction were analyzed.FT-IR and NMR analyses were performed to investigate the structure and hydrogen bond formation between the DES components.Addnl., mol. dynamic (MD) simulations were conducted to examine the mol. structure and formation mechanisms of these DESs.The results indicated that hydrogen bonds are formed between the hydroxyl group (-OH) of thymol and the carbonyl group (C=O) of acetamide/acetanilide.Thermodn. models, including regular solutions, NRTL, and Wilson, were employed to correlate the SLE phase diagrams of the studied mixtures, as determined by the DSC method.The phys. properties of the prepared DESs, such as m.p., d., speed of sound, refractive index and viscosity, were measured at different temperaturesDue to their hydrophobic nature, the DESs demonstrated stability in aqueous solutions and thus can be used to extract various analytes from aqueous environments.The obtained solvents were applied for the extraction of methylene blue, methyl orange, and rhodamine B from aqueous solutions, as well as from real textile wastewater samples.Finally, to achieve optimal extraction conditions, the effects of various factors on extraction efficiency were investigated.

2025-05-01·FOOD CHEMISTRY

Unveiling the nutritional composition and bioactivity of Ethiopian native fermented foods: Kocho and Injera

Article

作者: Desalegen, Asnake ; Birri, Dagim Jirata ; Assaye, Hirut ; Tigu, Fitsum ; Peñas, Elena ; Curiel, José Antonio ; Amare, Endale ; Martínez-Villaluenga, Cristina ; Legesse Bedada, Tesfaye ; Frias, Juana

Kocho and Injera are traditional Ethiopian foods but there is scarce information about their composition and potential health benefits. The aim of this research was to elucidate the nutritional and bioactivbe profiles of Kocho and Injera (white and brown) breads, and assessed the impact of in vitro digestion on their constituents. Kocho bread was rich in fiber (11.3 g/100 g dw), riboflavin (54.7 μg/100 g dw), and γ-aminobutyric acid (GABA, 36 mg/100 g dw). White and brown Injera had a notable content of protein (7.6-8.5 g/100 g dw), fiber (∼14 g/100 g dw), riboflavin (85.4-100.0 μg/100 g dw), polyols, sugars and oligosaccharides (123.0-261.3 mg/100 g dw), free amino acids (FAA,∼200 mg/100 g dw), GABA (46.0-55.5 mg/100 g dw), free phenolic compounds (FPC, 468.1-615.7 mg GAE/100 g dw), and antioxidant activity (399.2-888.3 mg TE/100 g dw). In vitro digestion increased FAA, peptides, GABA and FPC in the samples and two bioactive peptides were identified per sample.

项与 D-Galactose 相关的新闻（医药）

2025-03-11

·药物分子设计

哈佛大学发现，蘑菇中的这种成份，可增强线粒体功能，并延长寿命

买科研服务（代计算、代测试、超算机时），送老李校长“科研理工男士情感课” 第一性原理计算解决50年悬而未决难题：半导体中铜为何扩散更快？ Ab initio及第一性原理入门参考书介绍《海贼王》告诉你，做科研为什么不能闭门造车…… 985博导亲测：用DeepSeek写国自然本子，3天完成30天工作量题图 | Unsplash 撰文 | 宋文法麦角硫因（EGT），是一种含硫氨基酸，具有抗氧化、抗衰老、抗炎、细胞保护等作用，主要存在于蘑菇（如香菇、杏鲍菇）、动物组织及某些豆类中。人体无法自行产生麦角硫因，因此必须通过食物摄入来满足生理需求。此前多项研究显示，麦角硫因会在人体组织中累积，水平随着年龄增长而下降，且与年龄相关的疾病呈负相关。因此，麦角硫因被称为“长寿维生素”。目前，尚不清楚其直接和生理相关分子的机制。近日，哈佛大学医学院丹娜法伯癌症研究所的研究人员在" Cell Metabolism "期刊上发表了一篇题为" Ergothioneine controls mitochondrial function and exercise performance via direct activation of MPST "的研究论文。研究显示，麦角硫因在运动后会在肌肉线粒体中积累，能直接与线粒体酶3-巯基丙酮酸硫转移酶（MPST）结合并激活它，从而增强线粒体呼吸作用和运动表现。此外，膳食补充麦角硫因可以进一步增强小鼠模型的运动表现。图：参考文献【1】在这项研究中，研究人员分析了线粒体表面带有可检测标签的小鼠模型，检测了运动训练后肌肉线粒体中的代谢物变化，并鉴定了麦角硫因的直接分子靶点，以及通过细胞培养和小鼠模型，测试了麦角硫因对线粒体呼吸和运动表现的影响。结果发现，在4周的运动训练后，麦角硫因在肌肉线粒体中的积累量显著增加，几乎翻倍，而在肝脏和心脏线粒体中并未积累。进一步分析发现，转录辅激活因子PGC-1α，能够通过调控SLC22A4（EGT的转运蛋白）的表达，来控制肌肉中麦角硫因的水平。蛋白质组学分析发现，麦角硫因可以直接与线粒体酶3-巯基丙酮酸硫转移酶（MPST）结合并激活它，从而增强线粒体呼吸作用。图：参考文献【1】为了测试麦角硫因对运动表现进一步增强的影响，研究人员给训练期间的小鼠喂食富含麦角硫因的饮食，结果发现，富含麦角硫因的饮食可以显著提高小鼠的运动表现，包括跑步速度和总跑步距离。当研究人员敲除了MPST后，发现富含麦角硫因的饮食则不能提高敲除小鼠的运动表现，表明EGT-MPST轴是调节线粒体功能和运动表现的关键分子机制。综上，结果表明，麦角硫因可以直接与MPST结合并激活它，从而增强线粒体呼吸作用，从而提高运动表现，EGT-MPST轴是调节线粒体功能和运动表现的关键分子机制。此外，通过饮食补充麦角硫因，可以进一步增强运动表现。值得一提的是，麦角硫因还有助于促进整体健康，并延长寿命。 2025年1月，德国莱布尼茨分析科学研究所的研究人员在" Cell Metabolism "期刊上发表了一篇题为" Ergothioneine improves healthspan of aged animals by enhancing cGPDH activity through CSE-dependent persulfidation "的研究论文。研究显示，膳食补充麦角硫因可延长老年线虫、大鼠的寿命，并改善了整体健康，减少了与年龄相关的生物标志物，同时，麦角硫因提升了NAD+水平。图：参考文献【2】 2024年10月，华中农业大学的研究人员在" Food & Function "期刊上发表了一篇题为" Ergothioneine improves cognitive function through ameliorating mitochondrial damage and decreasing neuroinflammation in a d-galactose-induced aging model "的研究论文。研究显示，麦角硫因具有抗衰老作用，它可以改善小鼠模型衰老引起的氧化应激、神经炎症和线粒体功能，从而改善小鼠的认知功能，为改善年龄引起的认知障碍提供了一种饮食策略。图：参考文献【3】参考文献： 1、https://doi.org/10.1016/j.cmet.2025.01.024 2、https://doi.org/10.1016/j.cmet.2024.12.008 3、https://doi.org/10.1039/D4FO02321H 声明：本文仅做学术分享，不构成任何建议。

临床研究

2024-04-10

·E药经理人

喜鹊医药1类创新药物TBN可改善肌肉衰老与运动障碍 | 最新研究成果

广州2024年4月7日讯2024年3月，国际学术期刊《Biomedicine & Pharmacotherapy》刊登了喜鹊医药核心研发团队成员王玉强教授、张在军博士、孙业伟博士、张高小博士与暨南大学药学院、深圳市疾病预防控制中心深圳市现代毒理学重点实验室等多家机构成员合作研究的最新成果。该成果以《Tetramethylpyrazine Nitrone alleviates D-galactose-induced murine skeletal muscle aging and motor deficits by activating the AMPK signaling pathway》为题，详细揭示了喜鹊医药自主研发的1类创新药物硝酮嗪(TBN)在改善肌肉衰老、运动障碍及增强线粒体功能等方面的积极效果。研究团队采用D-半乳糖诱导的小鼠模型，深入研究了TBN对肌肉衰老和运动障碍的药效及作用机理。研究结果显示，TBN能够逆转包括p16、p21、鞘磷脂和端粒长度在内的多种衰老标志物水平，并增加腓肠肌组织重量，展示出改善肌肉衰老的显著药效。此外，通过对小鼠进行步态分析、爬杆测试和拉力测试等行为学评估，研究团队进一步发现了TBN在改善小鼠运动障碍方面的显著作用。同时，TBN对肌肉纤维化、炎症反应和线粒体功能的积极调节作用也在研究中得到了充分验证。TBN是中药川芎活性成分川芎嗪经化学结构修饰后得到的全新化学药物，由喜鹊医药创始人王玉强教授及其团队自主设计开发，具有多功能作用机理。TBN能够穿透血脑屏障，有效抑制钙离子超载、高效清除自由基、抑制炎症，并能够通过激活AMPK/PGC-1/Nrf2/HO-1信号通路显著增强线粒体功能，促进ATP的产生。此外，TBN还能通过抑制mTOR激活自噬通路，有效清除受损细胞组分和毒性蛋白。得益于新颖独特的作用机理，喜鹊医药TBN在包括本研究在内的多项与年龄及运动功能相关疾病的研究中展现出了很大的应用潜力，并在治疗缺血性脑卒中(AIS)、糖尿病肾病(DKD)和肌萎缩性侧索硬化症(ALS)等多项临床研究中取得了关键性进展，推进至临床II/III期阶段。特别值得一提的是，喜鹊医药近期完成的TBN治疗ALS的临床II期的试验结果显示，TBN治疗显著延缓ALS患者握力下降(P=0.037)，为患者运动功能带来了实质性的改善。推荐阅读：硝酮嗪能否解冻 ALS在人口老龄化趋势日益加剧的背景下，老年疾病的治疗与预防已成为社会关注的焦点，本项研究成果为解决肌肉衰老和运动障碍的治疗难题提供了新的视角和治疗策略，有望为相关患者带来福音。喜鹊医药将继续对TBN进行深入研究，挖掘其在改善衰老和运动障碍方面的潜力，为健康报喜。关于喜鹊医药广州喜鹊医药有限公司(简称喜鹊医药)是由国际知名药物化学家王玉强教授创办的临床阶段“First-in-Class”创新药物研究开发企业。秉持“求真务实，临床需求导向”的价值理念，基于小分子创新药物研究开发平台，喜鹊医药已经在心、脑血管及中枢神经系统疾病领域布局多条具有国际市场前景的药物管线，其中脑卒中(AIS)、糖尿病肾病(DKD)和肌萎缩侧索硬化(ALS)即将开展III期临床试验，另有II期临床项目7项，美国临床批件2项。喜鹊医药先后获得7项国家“新药创制”重大专项，获评广州市创业领军团队、广东省心脑血管与神经退行性疾病创新化学药物研发工程技术研究中心、第十届中国创新创业大赛生物医药组全国第二名等荣誉；喜鹊医药及其子公司已累计申请国内外专利90余项，已授权60余项，PCT专利20余项；与十余所高校、科研院所及百余家临床研究机构建立了合作关系。喜鹊医药已完成多轮融资，获得了包括仙瞳资本、康恩贝集团、中银粤财、科金控股等专业机构的持续支持。厚积薄发，喜鹊医药将持续为满足临床未满足需求而努力，为千万家庭之健康报喜。

临床2期

2024-03-28

·FierceBiotech

Avalo signals change in fortunes by snapping up AlmataBio for ex-Lilly inflammatory drug

Avalo only has eyes for the drug and won’t be taking on any of Almata’s staff. Avalo Therapeutics is handing over more than $22 million in stock and cash to acquire AlmataBio for a phase 2-ready monoclonal antibody for hidradenitis suppurativa (HS). The anti-IL-1β mAb, dubbed AVTX-009, has its origins at Eli Lilly. Avalo CEO Garry Neil, M.D., said the antibody has a “high probability of success for the treatment of HS as evidenced by recent data readouts validating inhibition of IL-1β in this disease.” “We believe that HS is a multi-billion-dollar commercial opportunity and that AVTX-009 has the potential to be best-in-class and best-in-indication because of its target, half-life, and potency, which may allow for strong efficacy and convenient dosing,” Neil added in a post-market release yesterday. Avalo will make AVTX-009 its lead asset, ahead of quisovalimab, an anti-LIGHT mAb in phase 2 development for ulcerative colitis, and AVTX-008, a BTLA agonist fusion protein in preclinical development. The biotech expects to read out topline results from a phase 2 study of AVTX-009 in HS in 2026, and also alluded to plans to evaluate the antibody in another chronic inflammatory indication. To get its hands on the drug, Avalo is paying out $15 million in stock and a further $7.5 million in cash to acquire Almata outright. Almata’s former stockholders are also in line for a $5 million payout when the first patient is dosed in the phase 2 trial and $15 million if a patient is dosed in a phase 3 trial. The acquisition of privately-held Almata marks the end of a short life for the biotech, which was set up in April 2023 with the aim of identifying and licensing AVTX-009. While Almata will become a subsidiary of Avalo, the new owner only has eyes for the drug itself and won’t be taking on any of Almata’s staff. "We are pleased that Avalo recognizes the promise of AVTX-009, an important potential treatment option for patients with inflammatory diseases,” Almata’s now-former CEO Patrick Crutcher said in the release. “AlmataBio was founded to identify, acquire, and accelerate the development of clinically meaningful therapies, and we are proud of the contribution of the talented AlmataBio team to this mission,” Crutcher added. “We look forward to the advancement of AVTX-009 into a phase 2 trial in HS under Dr. Neil’s stewardship.” Avalo hasn’t had an easy time in recent years. Back in 2022, the company was forced to cut down its pipeline and lost a chunk of its C-suite. Only last summer, the biotech had to work through a default with creditors before selling off its rare disease meds AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) to AUG Therapeutics. But with $35 million in debt eliminated and potentially up to $45 million in milestone payments to come from the offloaded AVTX-800 series, Avalo ended 2023 in a better place, even if it only had $10 million in the bank. Luckily, Avalo’s money worries have now been eased, with the company also announcing yesterday a $185 million raise via a private placement of various types of stock. The funding is expected to fuel the phase 2 trial of AVTX-009 and beyond into 2027. Investors appeared relieved at Avalo’s change in fortunes, sending the biotech’s stock rocketing over 330% in pre-marketing trading this morning to $20.50 from a Wednesday closing price of $4.75.

临床2期并购临床3期临床1期

100 项与 D-Galactose 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D04291	D-Galactose	V04CE01	DB11735

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
先天性糖基化障碍	临床2期	美国	National Institute of Neurological Disorders & Stroke	2025-06-01
XIV型糖原贮积病	临床2期	美国	Icahn School of Medicine at Mount Sinai	2025-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ISTH2022	N/A	血友病A	-	Macrophage Galactose Lectin (MGL)	鏇繭鏇範鹽願襯衊夢齋(選製憲蓋獵鏇衊築糧積) = 鑰積範繭糧齋艱膚繭鑰壓鏇鹽艱鹽憲夢廠廠鹽 (鬱簾鹽夢醖夢膚鹽範選 ) 更多	-	2022-07-09
NCT01113385 (CTgov)	N/A	局灶性节段性肾小球硬化症 \| 蛋白尿 \| 特发性抗类固醇的肾病综合征	7	D-Galactose	獵觸繭網鑰願淵餘夢窪(鹽繭鏇築齋遞築範鬱襯) = 築簾壓窪鏇壓選膚繭鹹積願顧衊壓淵選齋簾壓 (齋繭鬱齋構衊鹽願蓋廠, 0.11) 更多	-	2014-09-15
ASN2011	N/A	特发性抗类固醇的肾病综合征 FSPF	52	Oral Galactose	積艱廠淵淵網鏇壓蓋膚(餘鏇夢鹹膚廠製網獵艱) = UPC did not improve after therapy (12.6±9.4 pre and 27.4±31.9 post- therapy) 積醖顧齋膚製簾蓋繭壓 (鹽壓獵鹹廠繭簾範窪顧 ) 更多	不佳	2011-11-08